for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

bluebird bio Inc

BLUE.OQ

Latest Trade

89.53USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

84.01

 - 

163.33

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
89.53
Open
--
Volume
--
3M AVG Volume
13.97
Today's High
--
Today's Low
--
52 Week High
163.33
52 Week Low
84.01
Shares Out (MIL)
55.27
Market Cap (MIL)
4,948.26
Forward P/E
-6.61
Dividend (Yield %)
--

Next Event

Q3 2019 bluebird bio Inc Earnings Release

Latest Developments

More

Bluebird Bio, Novo Nordisk In Research Agreement To Develop Genome Editing Candidates For Haemophilia, Other Genetic Diseases

bluebird bio Presents Updated Data From Phase 2/3 Clinical Study Of Lenti-D Gene Therapy For Cerebral Adrenoleukodystrophy

Bluebird Bio Inc Reports Quarterly Loss Per Share Of $3.55

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About bluebird bio Inc

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Industry

Biotechnology & Drugs

Contact Info

60 Binney St

+1.339.4999300

http://www.bluebirdbio.com

Executive Leadership

Daniel S. Lynch

Independent Chairman of the Board

Nick Leschly

President, Chief Executive Officer, Director

William D. Baird

Chief Financial Officer

Jason F. Cole

Chief Operating Officer and Legal Officer, Secretary

Kory James Wentworth

Principal Accounting Officer, Vice President - Finance, Treasurer

Key Stats

2.13 mean rating - 23 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.0K
EPS (USD)

2016

-7.070

2017

-7.710

2018

-10.680

2019(E)

-13.560
Price To Earnings (TTM)
--
Price To Sales (TTM)
87.52
Price To Book (MRQ)
3.02
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-37.34
Return on Equity (TTM)
-34.60

Latest News

Latest News

Bluebird prices gene therapy at 1.58 million euros over 5 years

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

Bluebird prices gene therapy at 1.575 mln euros over five years

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

EMA panel recommends approval of Bluebird Bio's first gene therapy

A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

EMA panel recommends approval of Bluebird Bio's first gene therapy

A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

BRIEF-FDA Grants Breakthrough Therapy Designation To Lenti-D For The Treatment Of Cerebral Adrenoleukodystrophy

* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO LENTI-D™ FOR THE TREATMENT OF CEREBRAL ADRENOLEUKODYSTROPHY

Medigene in for up to $1.5 billion under broader pact with Bluebird Bio

German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

Medigene broadens alliance on T-cell receptors with Bluebird Bio

German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

BRIEF-Bluebird Bio Reports Qtrly Net Loss Per Share $2.31

* BLUEBIRD BIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

BRIEF-Bluebird Bio And Celgene Corporation To Co-Develop Anti-Bcma Car T Cell Therapy Bb2121 In The U.S.

* BLUEBIRD BIO AND CELGENE CORPORATION ENTER INTO AGREEMENT TO CO-DEVELOP AND CO-PROMOTE ANTI-BCMA CAR T CELL THERAPY BB2121 IN THE UNITED STATES

BRIEF-Bluebird Bio Reports Q4 Loss Per Share $2.52

* BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

BRIEF-Celgene Says Bluebird Car-T Therapy Remains A Top Priority

* CELGENE CEO SAYS WORKING WITH BLUEBIRD BIO TO DEVELOP BB2121 CAR-T THERAPY FOR MYELOMA REMAINS A TOP PRIORITY

Bluebird to seek approvals for three treatments by end of 2019

U.S. biotech bluebird bio Inc, which does not yet have any marketed products, expects to be able to file for regulatory approval of three novel treatments by the end of 2019, chief executive Nick Leschly announced on Tuesday.

BRIEF-Bluebird Bio Expects Three Regulatory Filings By End 2019

* BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019

BRIEF-Merck And Bluebird Bio Sign Supply Agreement For Commercial Production Of Viral Vectors

* MERCK AND BLUEBIRD BIO SIGN SUPPLY AGREEMENT FOR COMMERCIAL PRODUCTION OF VIRAL VECTORS Source text - http://bit.ly/2DfAvDy Further company coverage: (Gdynia Newsroom)

BRIEF-Bluebird Bio Prices Public Offering Of 3.2 Mln Shares At $185/Share

* BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Bluebird Bio Announces Proposed Public Offering Of Common Stock

* BLUEBIRD BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-bluebird bio And TC BioPharm Announce Strategic Collaboration

* BLUEBIRD BIO AND TC BIOPHARM ANNOUNCE STRATEGIC COLLABORATION TO RESEARCH AND DEVELOP GAMMA DELTA CAR T CELL PRODUCT CANDIDATES FOR CANCER IMMUNOTHERAPY

BRIEF-Bluebird Bio Acquires Manufacturing Facility In North Carolina

* BLUEBIRD BIO ACQUIRES MANUFACTURING FACILITY IN NORTH CAROLINA AND EXECUTES MULTIPLE GLOBAL SUPPLY AGREEMENTS TO ENHANCE ABILITY TO DELIVER GENE THERAPIES TO PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Bluebird Bio says to receive $15 mln option exercise payment from Celgene​

* Bluebird Bio Inc - to receive $15 million option exercise payment from Celgene

BRIEF-Bluebird Bio appoints Mary Lynne Hedley, Ph.D. to board of directors

* Bluebird Bio appoints Mary Lynne Hedley, Ph.D. to board of directors Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up